Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This abstract discusses finasteride and dutasteride's mechanisms in treating androgenetic alopecia and notes FDA approval for finasteride, but reports no new clinical results.

This thesis reviews current therapeutic approaches for ARFID and provides preliminary insights into enhancing treatment and care in Australia, including an evaluation of a pilot dietetic-led cognitive-behavioral therapy intervention.

This study reported that a liquid-liquid extraction method using methyl tert-butyl ether and methylene chloride was most effective for extracting dutasteride and its internal standard from rat plasma.

This study developed a method for designing peptide-based PROTAC drugs using advanced AI models, successfully identifying peptides that bind to specific receptors and incorporating them into a potential transdermal treatment for androgenetic alopecia.

This study reported the development of two highly sensitive ELISA assays to detect banned substances finasteride and dutasteride in human urine, offering better sensitivity than existing HPLC/MS/MS methods.

In this study, the Tibot AI application showed high diagnostic accuracy for adnexal and pigmentary disorders and cutaneous tumors in dermatology, but was less effective for immunological disorders and infestations, suggesting the need for further dataset refinement.

This study found that tenofovir alafenamide fumarate (TAF) is an effective and safer alternative to tenofovir disoproxil fumarate (TDF) for chronic hepatitis B, with fewer long-term side effects like nephrotoxicity and decreased bone density.

This article discusses the side effects of androgen deprivation therapy for nonmetastatic prostate cancer, highlighting the need for clinical trials to systematically study these effects.

In this study, researchers developed a novel TA-encapsulated microneedle applicator that successfully promoted hair growth and reduced inflammation in a C3H/HeJ mouse model of alopecia areata, potentially offering an improved alternative to existing treatments.

This study observed that oral tofacitinib was reasonably well-tolerated but had limited efficacy in treating alopecia areata, with a clinical response seen in 41.4% of patients over six months.

Intramuscular triamcinolone and pulse therapy with oral predonine are effective for alopecia areata with manageable side effects, but better relapse prevention is needed.

This review found dutasteride to be effective, safe, and well-tolerated for treating symptomatic BPH and provides expert commentary on its use, though the relationship with high-grade prostate cancer remains unclear.

This study observed that men receiving dutasteride for benign prostatic hyperplasia did not show significant differences in neuropsychological assessments compared to a control group not on dutasteride.

This study suggests that simple absolute threshold monitoring rules for compliance using the biomarker DHT perform similarly to more complex methods in the Prostate Cancer Prevention Trial.

This study in rats suggests that combining the 5 alpha-reductase inhibitor 4-MA with the antiandrogen Flutamide may enhance prostate cancer therapy by additively inhibiting prostatic growth and mRNA levels of androgen-sensitive prostatic binding proteins.

This study reports on a new semantic annotation approach used to identify substances in MEDLINE abstracts responsible for adverse drug reactions, with promising performance shown by a prototype system.

This study classified dutasteride, fesoterodine, and finasteride as beneficial for older or frail elderly patients, while suggesting caution or avoidance of α-blockers and antimuscarinics in this group.

This study found that autologous γdTregs displayed significant protective effects on alopecia areata-affected human scalp hair follicles in both ex vivo and in vivo settings, suggesting potential for future cell-based therapy.

This study developed a validated HPLC method for accurately estimating dutasteride and its related compounds in capsules, suitable for routine and stability sample analysis.

This study found that dutasteride improved maximum urinary flow rate more effectively than finasteride when used in combination therapy with tamsulosin for treating benign prostatic hyperplasia over six months.

Dutasteride 0.5mg was found to be more effective than finasteride 1mg in treating male pattern hair loss, with similar side effects.

This study found that arginine vasotocin is evolutionarily conserved across diverse taxa and may play roles in neuroendocrine, immune, and stress signaling, with potential antimicrobial applications.

In this study, researchers developed a new topical atraric acid formulation, AA-TF#15, which showed a significantly higher drug penetration and increased hair regrowth in mice compared to minoxidil and finasteride treatments, suggesting its potential effectiveness for treating scalp androgenic alopecia.

Temporal triangular alopecia is a non-scarring hair loss seen in some Asian children.

In this case report, upadacitinib was used to treat a 21-year-old female with severe alopecia areata, resulting in significant hair regrowth; however, rapid hair loss recurred soon after discontinuing the drug, illustrating its potential efficacy as well as the risk of relapse upon stopping treatment.

This study observed that topically applied RTA 408 reduced the severity of radiation-induced dermatitis in mice, with the highest dose significantly reducing and alleviating skin damage and associated inflammation.